Vitamin D supplementation in elderly nursing home residents increases 25(OH)D but not 1,25(OH)2D

Himmelstein, Sharon; Clemens, Thomas L.; Rubin, A. L.; Lindsay, Robert

doi:10.1093/ajcn/52.4.701

Cited by 81 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a posthoc analysis, the observed increase in 1,25(OH) 2 (37)(38)(39)(40)(41)(42)(43)(44). Comparisons between those reports and our findings are made difficult by differences in study design that include the ages of the subjects, type and dose of vitamin D administered, duration of vitamin D administration, baseline 25OHD levels, and assays used.…”

Section: Discussioncontrasting

confidence: 47%

Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23

Burnett-Bowie

Leder

Henao

et al. 2012

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives Fibroblast growth factor 23 is a phosphate-and vitamin D-regulating hormone. The objective of this study was to determine the effect of ergocalciferol administration on fibroblast growth factor 23 levels in healthy vitamin D-deficient subjects.Design, setting, participants, & measurements In this 12-week trial conducted in a clinical research center, 18-to 45-year-old subjects (n=90) with 25-hydroxyvitamin D levels #20 ng/ml (by chemiluminescent immunoassay) were randomized to weekly ergocalciferol treatment of 50,000 international units or placebo, while consuming a self-selected diet. Changes in fibroblast growth factor 23, 25-hydroxyvitamin D (by liquid chromatography/ tandem mass spectroscopy), 1,25-dihydroxyvitamin D, parathyroid hormone, and serum phosphate were measured.Results Mean 25-hydroxyvitamin D (P,0.0001), 1,25-dihydroxyvitamin D (P=0.01), and fibroblast growth factor 23 (P=0.003) increased in the treatment versus placebo group. In the treatment group, 25-hydroxyvitamin D increased from 1867 to 40612 ng/ml at week 4 (P,0.0001) and remained stable at 43612 ng/ml at week 12 (P,0.0001); 1,25-dihydroxyvitamin D increased from 42617 to 52618 pg/ml at week 4 (P,0.001) and then remained stable, and fibroblast growth factor 23 increased from 43617 to 60633 pg/ml at week 8 (P=0.001) and 74642 pg/ml at week 12 (P,0.0001). Urinary phosphate excretion increased within the treatment group, but parathyroid hormone and serum phosphate were unchanged.Conclusions Ergocalciferol administration increases circulating fibroblast growth factor 23. When measuring fibroblast growth factor 23, concurrent 25-hydroxyvitamin D measurements should be obtained, because vitamin D deficiency may lower circulating fibroblast growth factor 23 levels.

show abstract

Section: Discussioncontrasting

confidence: 47%

Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23

Burnett-Bowie

Leder

Henao

et al. 2012

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…In a recent study performed in osteomalacia, we have also shown that serum OC is a marker of the level of bone turnover, assessed by histomorphometry, and does not correlate with serum la,25(OH)2D (29). Moreover, in the elderly, low doses of vitamin D increase serum 250HD but not la,25(OH)2D3 (19,(30)(31)(32).…”

Section: Discussionmentioning

confidence: 95%

Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.

Szulc¹,

Chapuy²,

Meunier³

et al. 1993

J. Clin. Invest.

456

238

View full text Add to dashboard Cite

“…Previous research has demonstrated that vitamin D levels have a lag such that changes in behavior should not affect vitamin D levels for at least 6 to 8 weeks. 21,22 When we reanalyzed the data using only patients with samples taken within 2 months of the attack, vitamin D level still had a significant association with attack severity (data not shown).…”

mentioning

confidence: 99%

Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis

et al. 2014

View full text Add to dashboard Cite

Objective: To identify clinical and demographic features associated with the severity and recovery from acute optic neuritis (AON) episodes in patients with multiple sclerosis (MS).Methods: Adult (n 5 253) and pediatric (n 5 38) patients whose first symptom was AON were identified from our MS database. Severity measured by loss of visual acuity (mild attack #20/40, moderate attack 20/50-20/190, and severe attack $20/200) and recovery in visual acuity at 1 year after the attack (complete recovery #20/20, fair recovery 20/40, and poor recovery $20/50) were recorded. Demographic and clinical features associated with attack severity and recovery were identified using proportional odds logistic regression. For another group of patients, blood samples were available within 6 months of an AON attack. In this group, the impact of vitamin D level on the severity/recovery was also assessed.Results: Men (adjusted odds ratio [OR] 5 2.28, p 5 0.03) and subjects with severe attacks (adjusted OR 5 5.24, p , 0.001) had worse recovery. AON severity was similar between the pediatric and adult subjects, but recovery was significantly better in pediatric subjects in the unadjusted analysis Acute optic neuritis (AON) is an inflammatory disorder of the optic nerve and the initial presenting symptom of multiple sclerosis (MS) in approximately 15% to 20% of patients.1,2 There is wide variability in the severity and recovery from AON among patients with MS, and clinical predictors of AON severity or recovery are not well understood. Previous work has demonstrated that severity and recovery from the initial relapse are associated with severity and recovery for subsequent relapses, but factors specifically affecting AON attacks have not been sufficiently studied.

show abstract

Vitamin D supplementation in elderly nursing home residents increases 25(OH)D but not 1,25(OH)2D

Cited by 81 publications

References 26 publications

Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23

Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23

Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.

Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis

Contact Info

Product

Resources

About